Posts by Helene Kuhn
Sepset’s Sepsis Signature
BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.
Read MoreValidation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU
Miller et al., American Journal of Respiratory and Critical Care Medicine | SeptiCyte LAB appears to be a promising diagnostic tool to complement physician assessment of infection likelihood in critically ill adult patients with systemic inflammation.
Read MoreA Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies
Sampson et al., Scientific Reports | Data demonstrates the ability of a four-biomarker blood signature to discriminate viral and non-viral causes of systemic inflammation in a variety of clinical settings. Discussed is the investigation of how to determine if a blood-based signature could be discovered and show a host systemic response to viral infection.
Read MoreDiagnostic Accuracy of a Host Gene Expression Signature That Discriminates Clinical Severe Sepsis Syndrome and Infection-Negative Systemic Inflammation Among Critically Ill Children
Zimmerman et al., Critical Care Medicine | SeptiCyte Lab is able to discriminate clearly between clinically well-defined and homogeneous postcardiopulmonary bypass and clinically overt severe sepsis syndrome groups in children. A broader investigation among children with more heterogeneous inflammation-associated diagnoses and care settings is warranted.
Read MoreA Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts
McHugh et al., PLOS Medicine | SeptiCyte Lab is a rapid molecular assay that may be clinically useful in managing ICU patients with systemic inflammation. Further study in population-based cohorts is needed to validate this assay for clinical use.
Read MoreDevelopment and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis
Sutherland et al., Critical Care | A novel molecular biomarker test based on a panel of 42-gene expression markers has demonstrated a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients.
Read MoreImmunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour
Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so.
Read MoreImmunexpress vying for FDA clearance of its sepsis test
When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can’t find. That’s where Immunexpress (Seattle) comes in. The…
Read MoreImmunexpress to Submit Molecular ‘Immune Response’ Sepsis Assay to FDA in May
Immunexpress may finally be close to marketing a clinical test in the US. Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the company plans to submit the test in May to the US Food and Drug Administration and hopes it can gain marketing clearance by the…
Read MoreImmunexpress, Collaborators Publish Clinical Validation of Host-Response Sepsis Assay
Immunexpress, Inc., committed to improving outcomes for suspected sepsis patients, announced the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis in PLOS Medicine.
Read More